SCHEMBL23249633

SCHEMBL23249633

CCc1c(C)nc(-n2nc(C)c(C)c2NCc2ccccc2Cl)[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ POLB P06746 2/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HSD17B10 Q99714 3/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ SLC2A1 P11166 2/20 0.43
▸ TNKS2 Q9H2K2 1/20 0.42
▸ DCTPP1 Q9H773 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ PDE9A O76083 2/20 0.40
▸ P2RX7 Q99572 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23249628 0.85 POLB (0.43) POLBMEN1TSHRKMT2AMAPK1
SCHEMBL23249591 0.85 MEN1 (0.53) SMN1; SMN2POLBMEN1TSHRKMT2A
SCHEMBL23249355 0.81 POLB (0.43) SMN1; SMN2POLBMEN1TSHRKMT2A
SCHEMBL23249726 0.81 SLC2A1 (0.49) SMN1; SMN2POLBMEN1TSHRKMT2A
SCHEMBL23249589 0.78 POLB (0.43) SMN1; SMN2POLBMEN1TSHRKMT2A
SCHEMBL23249507 0.77 ADCY8 (0.51) SMN1; SMN2POLBMEN1TSHRKMT2A
SCHEMBL23249710 0.76 POLB (0.48) SMN1; SMN2POLBMEN1TSHRKMT2A
SCHEMBL23249308 0.76 SLC2A1 (0.52) POLBMEN1TSHRKMT2AMAPK1
SCHEMBL23249605 0.75 LMNA (0.41) POLBMEN1TSHRKMT2AMAPK1
SCHEMBL23249529 0.74 SLC2A1 (0.49) SMN1; SMN2POLBMEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139190-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-05-02 — — US disclosed
WO-2021077102-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-22 — — WO disclosed
WO-2021077102-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139190-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS TUBB, TUBB1, TUBA1C SMN1; SMN2 2652/4885POLB 135/4885MEN1 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback